AbCellera Biologics Inc.
Price Action
Technical Summary
CONSOLIDATINGAbCellera Biologics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 66), indicating performance broadly in line with the market. Earnings growth of 75% provides fundamental context to the price action. However, price is extended 36% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.07 | +23.98% | ABOVE |
| 50 SMA | $3.72 | +35.65% | ABOVE |
| 100 SMA | $3.68 | +37.03% | ABOVE |
| 150 SMA | $4.02 | +25.24% | ABOVE |
| 200 SMA | $4.14 | +21.67% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ABCL in an uptrend right now?
ABCL has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ABCL overbought or oversold?
ABCL's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is ABCL outperforming the market?
ABCL has a Relative Strength (RS) Rating of 66 out of 99. ABCL is performing about average compared to the market.
Where is ABCL in its 52-week range?
ABCL is trading at $5.04, which is 77% of its 52-week high ($6.52) and 68% above its 52-week low ($1.94).
How volatile is ABCL?
ABCL has a Beta of 2.31 and 52-week volatility of 76%. It's more volatile than the S&P 500 - expect bigger swings.